Manipal Acunova is a venture promoted by MEMG International India Private Limited and Acunova Life Sciences Private Limited.
The Company has mobilised more than US$ 20 Million through equity and debt. The Private Equity Investments is represented by OrbiMed Advisors, a Healthcare Fund Management company.
Key Investors
Acunova Life Sciences Private Limited (ALS)
ALS is a company specializing in investments in Pharma Services, Clinical Services, medical devices and Stem cell therapeutics space in Asia and Europe. It has investors with vast experience in the pharmaceutical and health care domain. Apart from domain skills, ALS brings value through its strategic investments in Life Sciences area.
MEMG International India Private Limited
MEMG International India Private Limited can look back on 53 years of patient care, education and research.
Manipal's Medical Schools, Pharmacy School and Biotechnology program are research-oriented and rank amongst the top five in India. Some of the specialized colleges under the banner include medical colleges, dental colleges, and institutions imparting education in nursing, allied health, pharmacy, engineering, management, communication and journalism.
All the healthcare institutions and teaching hospitals have multi-stream facilities covering the entire spectrum from secondary to super -specialty care. Furthermore, community health work outreach camps and clinics have been conducted to bring healthcare to the doorstep of people in the villages.
OrbiMed Advisors (Investors)
OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages a series of venture capital funds and public equity investment funds. OrbiMed seeks to be the capital provider of choice for life sciences companies pursuing growth and new opportunities. |
|
| |
Ecron Acunova Subsidiaries
As a CRO we operate in over 25 countires with appropriate legal structure. Significant subsidiaries are given below.
Acunova Life Sciences Inc
Acunova Life sciences Inc, a wholly owned subsidiary of Manipal Acunova, is located in Princeton NJ and manages partner relationships in USA. Founded in 2005, ALS Inc. offers strategic and regulatory consulting services in clinical development.
Ecron Acunova GmbH
Ecron Acunova GmbH, a wholly owned subsidiary of Manipal Acunova Ltd, is a European expert CRO for clinical development of medicinal products for human use. Founded in 1986 by Dr. Wiedey and headquartered in Frankfurt, the company has conducted trials for submission to Regulators worldwide.
Studies have been audited by FDA and by European Regulators. Ecron Acunova GmbH has direct operations in Germany, Ukraine, Poland, Spain, UK, Italy, Russia and Czech Republic and through partners in key countries in Europe, Americas and Asia. Ecron Acunova has built an enviable reputation for quality.
Ecron Acunova A/S
Ecron Acunova A/S offers a full range of CRO services on drug development to investors, inventors, and entrepreneurial companies, and has a strong presence in the Nordic area. They meet the need for getting to the market fast and efficiently. Additionally, they work as a strategic partner for the local pharmaceutical, biotech, and medical device industry in clinical development, contributing to fulfillment of their goals and future demands for clinical documentation. Our wide range of services within drug and medical device development is managed by highly qualified and motivated employees.
Ecron Acunova Company Limited, Thailand
Ecron Acunova Company Ltd., (EACL), a 74% subsidiary of Ecron Acunova, is an expert CRO for clinical development. The company is a collaboration with Jamjuree Innovations Co., Ltd. a company fully owned by Chulalongkorn University in Bangkok, one of Southeast Asia’s leading academic institutions with a highly acclaimed Faculty of Medicine. The CRO was operational for three years prior to acquisition by Ecron Acunova. It employs regional pioneers and experts in ICH-GCP guided clinical research. EACL is the centre of excellence for HIV and nutritional studies.
|
|
